Arvinas Inc
NASDAQ:ARVN
| Market Cap (Intraday) | 2.35B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $44.76 |
| 50-Day MA | $48.20 |
| 200-Day MA | $56.85 |
Arvinas Inc Stock, NASDAQ:ARVN
5 Science Park, 395 Winchester Avenue, New Haven, Connecticut 06511
United States of America
Phone: +1.203.535.1456
Number of Employees: 280
Description
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.